T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2476
MannKind Corp
MNKD
$1.2B
| $407K | ﹤0.01% |
93,091
-4,902
| -5% | -$22.7K |
|
2477
Amdocs
DOX
$6.23B
| $406K | ﹤0.01% |
5,427
-2,129
| -28% | -$160K |
|
2478
Mesa Laboratories
MLAB
$633M
| $406K | ﹤0.01% |
1,237
-111,557
| -99% | -$35M |
|
2479
Titan International
TWI
$438M
| $404K | ﹤0.01% |
36,854
-1,200
| -3% | -$9.41K |
|
|
GHL
2480
DELISTED
Greenhill & Co., Inc.
GHL
| $404K | ﹤0.01% |
22,505
-300
| -1% | -$5.16K |
|
2481
Construction Partners
ROAD
$6.73B
| $400K | ﹤0.01% |
13,600
-426
| -3% | -$14.9K |
|
2482
TriMas Corp
TRS
$1.39B
| $398K | ﹤0.01% |
10,760
-705
| -6% | -$24.3K |
|
|
EBIX
2483
DELISTED
Ebix Inc
EBIX
| $397K | ﹤0.01% |
13,049
-3,604
| -22% | -$115K |
|
|
FIRY
2484
Firy Inc
FIRY
$158M
| $396K | ﹤0.01% |
2,663
-1,631
| -38% | -$314K |
|
2485
Stem
STEM
$55.9M
| $396K | ﹤0.01% |
1,044
-968
| -48% | -$420K |
|
2486
AMC Global Media
AMCX
$496M
| $394K | ﹤0.01% |
11,445
-1,875
| -14% | -$78K |
|
2487
Liberty Latin America Class A
LILA
$1.67B
| $394K | ﹤0.01% |
49,690
-1,162
| -2% | -$9.66K |
|
|
FRG
2488
DELISTED
Franchise Group, Inc.
FRG
| $392K | ﹤0.01% |
7,518
-1,285
| -15% | -$57.8K |
|
|
AGEN
2489
Agenus
AGEN
$315M
| $391K | ﹤0.01% |
6,181
+3,909
| +172% | +$308K |
|
2490
Axsome Therapeutics
AXSM
$11.2B
| $390K | ﹤0.01% |
10,314
-9,796
| -49% | -$360K |
|
2491
First Commonwealth Financial
FCF
$2.19B
| $390K | ﹤0.01% |
24,258
-4,485
| -16% | -$68.1K |
|
|
CNSL
2492
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $388K | ﹤0.01% |
51,871
-1,400
| -3% | -$11.5K |
|
2493
Veru
VERU
$46M
| $387K | ﹤0.01% |
6,579
+1,555
| +31% | +$119K |
|
2494
AMERISAFE
AMSF
$504M
| $386K | ﹤0.01% |
7,176
-375
| -5% | -$21K |
|
2495
C3.ai
AI
$1.58B
| $385K | ﹤0.01% |
12,332
+1,140
| +10% | +$46.2K |
|
|
JAMF
2496
DELISTED
Jamf
JAMF
| $385K | ﹤0.01% |
10,119
+54
| +0.5% | +$2.09K |
|
2497
Keros Therapeutics
KROS
$211M
| $384K | ﹤0.01% |
+6,567
| New | +$327K |
|
|
SWCH
2498
DELISTED
Switch, Inc. Class A Common Stock
SWCH
| $382K | ﹤0.01% |
+13,343
| New | +$349K |
|
2499
TTM Technologies
TTMI
$14.6B
| $381K | ﹤0.01% |
25,573
-24,820
| -49% | -$346K |
|
|
ORC
2500
Orchid Island Capital
ORC
$1.32B
| $379K | ﹤0.01% |
16,860
+81
| +0.5% | +$1.94K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.